GlassScriptPhysician profile
Ramon Marcos Sanchez
NPI 1487678116
$8,043.81
in general payments reported to CMS, 2019-2025
56 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $492 · 2021: $1,592 · 2022: $1,811 · 2023: $1,333 · 2024: $710 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,034.44 | 2019-2022 | |
| Eisai INC. | $613.79 | 2019-2024 | |
| Sk Life Science, INC. | $541.06 | 2020-2024 | |
| Abbvie INC. | $539.97 | 2021-2025 | |
| Lilly USA, LLC | $478.17 | 2019-2025 | Amyvid, Kisunla |
| Ucb, INC. | $323.84 | 2019-2024 | Nayzilam |
| Sumitomo Pharma America, INC. | $310.18 | 2023-2024 | Aptiom |
| Pfizer INC. | $296.28 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $287.13 | 2023-2025 | Fycompa |
| Biohaven Pharmaceutical Holding Company LTD. | $273.12 | 2022 | |
| Neurocrine Biosciences, INC. | $254.51 | 2019-2023 | Ingrezza, Ongentys |
| Biogen, INC. | $254.26 | 2019-2025 | Leqembi, Skyclarys, Tysabri |
| Acadia Pharmaceuticals INC | $243.26 | 2022-2025 | Nuplazid |
| Neurelis, INC. | $212.44 | 2021-2023 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $210.05 | 2020-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.